Roche’s Tecentriq+chemo combo shows first-line benefit in small cell lung cancer

pharmafile | September 26, 2018 | News story | Research and Development |  Cancer, Combo, Roche, chemotherapy, lung cancer, pharma, tecentriq 

Roche has unveiled new Phase 3 data for its cancer immunotherapy Tecentriq (atezolizumab) in combination with carboplatin and etoposide chemotherapy as a first-line treatment for previously-untreated extensive-stage small cell lung cancer (ES-SCLC), showing “significantly” improved rates of overall survival (OS) compared to chemotherapy alone.

Specifically, Roche’s combo extended OS by 12.3 months compared to 10.3 months with chemotherapy alone, while also improving progression-free survival by 5.2 months compared to 4.3 months.

The combo’s safety profile was found to be consistent with previous investigations. 56.6% of patients reported adverse events of grade 3 or 4 compared to 56.1% of those receiving chemotherapy alone.

“The results with this Tecentriq combination in the initial treatment of extensive-stage small cell lung cancer represent the first clinically meaningful advance in the disease in over 20 years,” said Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “Our goal is to find treatment options for all types of lung cancer, and we are eager to work with global health authorities to bring this Tecentriq regimen to people living with this particularly difficult-to-treat form of lung cancer as soon as possible.”

Advertisement

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

Cizzle Biotechnology expands US rollout of lung cancer blood test

Cizzle Biotechnology has launched the commercial rollout of its CIZ1B Biomarker Blood Test for lung …

The Gateway to Local Adoption Series

Latest content